Search En menu en ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

    Signature(s)

    Amount
    € 80,000,000
    Countries
    Sector(s)
    Spain : € 80,000,000
    Services : € 80,000,000
    Signature date(s)
    26/09/2024 : € 80,000,000
    Link to source

    Summary sheet

    Release date
    30 September 2024
    Status
    Reference
    Signed | 26/09/2024
    20230785
    Project name
    Promoter - financial intermediary
    IMMUNOLOGY RESEARCH CENTRE
    FUNDACION BANCARIA CAIXA D'ESTALVIS I PENSIONS DE BARCELONA LA CAIXA
    Proposed EIB finance (Approximate amount)
    Total cost (Approximate amount)
    EUR 80 million
    EUR 110 million
    Location
    Sector(s)
    • Services - Professional, scientific and technical activities
    Description
    Objectives

    The project will finance the new immunology research centre established by “la Caixa” Foundation in Madrid. The new Institute will be equipped with state-of-the-art facilities on premises of over 20 000 m2, designed to accommodate a team of more than 500, including scientists, technicians and administrators.

    The aim of the new biomedical research centre is to promote translational research in immunology. The centre will have a clear mission to collaborate with the scientific community and is intended to increase innovation and competitiveness in the healthcare sector, which is strategic for the European Union. The renovation of the foundation office building aims at improving its energy performance, in line with the EIB's climate action and environmental sustainability objectives.

    Additionality and Impact

    The Project supports the Bank's primary objective "Innovation, digital and human capital". It aims to create facilities dedicated to medical research, thereby contributing to the relevant European, national and regional policies in the respective areas, including the European Research Area. The Project supports medical research, including basic medical research, which, due to their nature as public goods, generate externalities to the benefit of society and the broader economy. Strategic investments in the medical research sector have been shown to yield long-term health benefits, as well as economic and social returns on investment that far exceed potential commercial returns. Establishing the new medical research centre, located in modern, fit-for-purpose premises, furnished with up-to-date equipment, organized in the way ensuring its optimal use, and operated by the Promoter experienced in establishing medical research centres and staffed by skilled researchers, should result in a number of benefits for the society, both locally and globally. Among other, the new institute will enable to retain and attract skilled researchers to Europe. Outputs of the Project, including new patents and spin offs, will add to an increase of EU's innovation and competitiveness and strengthening the EU economy. Finally, new research premises in the vital knowledge domain of immunology will help addressing major global health problems. EIB's involvement diversifies the Borrower's financing sources with customized terms. It also provides a signalling effect on the quality of the Project.  


    Environmental aspects
    Procurement

    Directive 2011/92/EU amended by 2014/52/EU on Environmental Impact Assessment (EIA) does not specifically cover re educational activities, leaving it at the discretion of the responsible competent authorities to request an EIA on the basis of the location and scale of the works concerned. However, research facilities may fall under Annex II of the Directive with respect to Urban Development. The Bank's services will verify during appraisal whether an EIA is required by the competent authority. The office building will be required to at least meet the energy efficiency targets as defined in Directive 2010/31/EU on the energy performance of buildings and Directive 2012/27/EU on energy efficiency. The Project is expected to contribute to climate action and environmental sustainability (CA&ES) objectives, in particular to climate mitigation. Social and environmental aspects as well as any aspects related to historical and cultural heritage will be verified during the appraisal.

    The promoter has been assessed by the EIB as being a private company not being subject to EU rules on public procurement or concessions. However, if at the project appraisal, the EIB were to conclude that the promoter is subject to the EU public procurement legislation then the European Commission will be duly informed, which will require the promoter to apply such rules.

    Milestone
    Under appraisal
    Approved
    Signed
    24 July 2024
    26 September 2024
    Link to source

    Disclaimer

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
    They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    News & Stories

    Other links

    General enquiries and comments

    The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
    Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
    Alternatively, the EIB can be contacted through its external offices.
    Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

    Media enquiries

    Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

    Complaints mechanism

    Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

    Zero tolerance against fraud and corruption

    The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

    Related publications